论文信息 - Waldenström's Macroglobulinemia - 字舞流文

Waldenström's Macroglobulinemia

E. Ocio | R. García-Sanz

[1] N. Gutiérrez,et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia , 2013, Leukemia.

[2] R. Fonseca,et al. Molecular pathogenesis of Waldenström’s macroglobulinemia , 2012, Haematologica.

[3] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[4] M. Dimopoulos,et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5] Marcos González,et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. , 2007, Haematologica.

[6] A. Órfão,et al. Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma. , 2005, Clinical lymphoma.

[7] S. Montoto,et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.